AMAG Pharma (AMAG) Reports Q4 Loss of $0.31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMAG Reports Fourth Quarter and Full Year 2016 Financial Results
February 14, 2017 7:01 AM EST2016 GAAP revenue increased 27% over 2015
Achieved record quarterly and annual net sales for Makena® and Feraheme®
Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2016.
Total GAAP revenue for the full year of 2016 increased approximately 27% to $532.1 million, primarily driven by record sales for both Makena® (hydroxyprogesterone caproate injection) and Feraheme® (ferumoxytol) and... More
